http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010043224-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10134
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
filingDate 1999-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2001-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20010043224-A
titleOfInvention Novel composition
abstract The novel vaccine composition of the present invention comprises hepatitis B antigen formulated with aluminum phosphate. The vaccine composition of the present invention may further contain inactivated hepatitis A virus, aluminum hydroxide and formol. Mixed hepatitis A and B vaccine formulations may optionally be administered to human subjects in a two dose regimen. Suitable formulations are illustrated.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101281098-B1
priorityDate 1998-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425901710
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID12092
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID712
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID10407
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID386463
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10176082
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1041
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID10407
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID12092
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5359268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16693906
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545463
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491804
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453694953

Total number of triples: 47.